Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

31,229 signal articles · 0 in last 24h · 160,153 total before filter · latest 3d ago
0last 24h
526last 7d
72● bullish (7d)
61● bearish (7d)
214publishers
AllMacro94Earnings152M&A53Regulatory10Product10Analyst15
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Charles Schwab Net New Assets Hit $64.8 Billion in August, a Record for the Month
Barrons.com19d agoneutral
Charles Schwab Net New Assets Hit $64.8 Billion in August, a Record for the Month

Charles Schwab’s stock was rising Tuesday morning after it reported hauling in $64.8 billion in core net new assets, a record for the month of August. Analysts watch the company’s asset-gathering figures closely to see how quickly Schwab is growing. The company said customers opened 424,000 new brokerage accounts in August, an increase of 11% compared with August 2025.

Investing.com19d agoneutral
Meta stock rises on cost-saving AI chip deployment plans

Investing.com -- Meta Platforms (NASDAQ:META) shares rose 2% Tuesday morning after Bloomberg reported the company plans to deploy new in-house artificial intelligence chips in data centers during the first half of next year. The stock later pared gains to up 0.75%.

Citi’s 11%+ RoTCE Target Signals Stronger Capital Efficiency
Insider Monkey19d agoneutral
Citi’s 11%+ RoTCE Target Signals Stronger Capital Efficiency

Citigroup Inc. (NYSE:C)’s CFO Gonzalo Luchetti said the bank expects return on tangible common equity (RoTCE) to come in slightly above 11% in 2026, while also indicating that Citi will increase stock buybacks from the $13 billion repurchased in 2025. The bank plans to accelerate roughly $500 million of investment by year-end, including spending on […]

Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market
Insider Monkey19d agoneutral
Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market

Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk’s Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly’s rapid share capture an important sign […]

Abbott Faces $384 Million Cost as Infant Formula Legal Risks Persist
Insider Monkey19d agoneutral
Abbott Faces $384 Million Cost as Infant Formula Legal Risks Persist

Abbott Laboratories (NYSE:ABT) has agreed to pay more than $384 million to resolve U.S. Justice Department allegations that it knowingly produced infant formula in potentially contaminated environments at its Michigan and Arizona facilities, including allegations of inadequate testing and failure to disclose positive contamination tests to regulators. The settlement resolves civil claims without an admission […]

From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure
Insider Monkey19d agoneutral
From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure

Novo Nordisk A/S (NYSE:NVO)’s decision to rebrand its day-to-day identity as “Novo” and launch a cultural reset is primarily a strategic response to the company’s loss of momentum in the obesity-drug market, rather than a financial restructuring in itself. Reuters reports that the company is trying to regain competitiveness as pressure from Eli Lilly intensifies. […]

ASML Eyes 110+ EUV Tools in 2028 as AI Chip Demand Accelerates
Insider Monkey19d agoneutral
ASML Eyes 110+ EUV Tools in 2028 as AI Chip Demand Accelerates

ASML Holding N.V. (NASDAQ:ASML) is examining ways to produce more than 110 EUV lithography systems in 2028, according to JPMorgan analysts following a meeting with CFO Roger Dassen. The company is already nearly sold out for 2027 and expects to produce at least 80 EUV systems that year, meaning output above 110 in 2028 would […]